This activity was developed for gastroenterologists and other health care professionals managing patients with HCV.
Statement of Need/Program Overview
The purpose of the activity is to improve the therapeutic management and patient outcomes for community based practitioners.
Upon completion of this activity, participants should be better able to:
Recognize the clinical trial data, AASLD treatment guidelines and approved product labeling for available therapies.
Identify patients who are good candidates for currently available therapy versus those patients that would benefit more from future therapies.
Use the knowledge gained to maximize clinical outcomes on a case-by-case basis.
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship of the Annenberg Center for Health Sciences at Eisenhower and Chronic Liver Disease Foundation. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.5 contact hours may be earned for successful completion of this activity.
Americans with Disabilities Act
The event staff will be glad to assist you with any special needs (i.e. physical, dietary, etc.).Please contact us prior to the event at 888-565-5321.
Each presenter is responsible for identifying local community based HCV specialists and/or gastroenterology practices that have the interest, office support, and are willing to treat more hepatitis C patients. Upon their recommendation, the nominated practice will be invited to participate in a series of two sequential meetings that are scheduled approximately 60-90 days apart from one another.
If your practice is interested in participating in an HCV Alliance meeting, please send a request to firstname.lastname@example.org. Space is limited; the request will be honored on a first come, first served basis.
This activity endorsed by the International Coalition of Hepatology Educational Providers and sponsored by the Chronic Liver Disease Foundation.
This activity Supported by:
AbbVie and Bristol-Myers Squibb
The goal of the HCV ALLIANCE program is to provide small group education in order to improve patient outcomes. The HCV ALLIANCE program will provide 2 sessions of in-depth, structured clinical guidance and support to select community based gastroenterologists while providing a "hands-on" consultative approach to education and training.
Small Group Sequential Educational Meeting Series
Led by the CLDF's Hepatology Centers of Educational Expertise (HCEE), the HCV ALLIANCE Program series will begin with a small group meeting between the HCEE and the community practice to review the latest clinical data, discuss patient management strategies and address specific clinical questions from the community practice. During this meeting, the mentor will ensure that the community practice is incorporating the current standard of care into practice.
Follow-Up Educational Sessions
Within 90 days of the initial small group educational meetings, the HCEE and/or a member of their HCV treatment team will lead a follow-up meeting with the community sites. During these meetings, the academic center will review components of patient treatment, compliance, and patient education with current therapies. They will formulate a plan for the practice in which they will review compliance and dosing intervals and lead a discussion on adverse event management strategies.